FBRX — Forte Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1419041 ·
Last close
$17.56
Market Cap
$359.61M
52W High
$35.80
52W Low
$15.51
ADV30
248,913
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,439,000 | -22,136,000 | 67,223,000 | 58,223,000 | 25,123,000 |
| Dec 2025 | 0 | — | -24,571,000 | -24,788,000 | 82,779,000 | 76,957,000 | 21,788,000 |
| Sep 2025 | 0 | — | -18,383,000 | -17,682,000 | 97,089,000 | 93,414,000 | 12,992,000 |
| Jun 2025 | 0 | — | -11,579,000 | -11,249,000 | 107,783,000 | 106,144,000 | 9,170,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,335,000
Investing CF
$-55,000
Financing CF
$71,757,000
CapEx
$-147,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.56
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-223,373,000
Inventory
—
Receivables
$817,000
ST Investments
$0
EBIT TTM
$-70,657,000
Pretax Income TTM
$-68,338,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,657,000 | -69,375,000 | 82,779,000 | 21,788,000 | — | -50,882,000 |
| Dec 2024 | 0 | -36,602,000 | -35,478,000 | 61,561,000 | 9,081,000 | — | -30,745,000 |
| Dec 2023 | 0 | -32,486,000 | -31,476,000 | 38,980,000 | 3,666,000 | — | -28,706,000 |
| Dec 2022 | 0 | -13,896,000 | -13,879,000 | 41,997,000 | 3,179,000 | — | -8,185,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | $359.32M | $4.49 | — |
| VSTM | Verastem, Inc. | $360.28M | $4.10 | — |
| LRMR | Larimar Therapeutics, Inc. | $360.47M | $3.47 | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $360.67M | $20.51 | — |
| GLSI | Greenwich LifeSciences, Inc. | $353.16M | $24.06 | — |
News headlines (Yahoo Finance, 1h cache)
One Forte Biosciences Insider Raised Stake By 30% In Previous Year
2026-06-13 13:24 · Yahoo
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
2026-05-11 20:01 · Yahoo
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
2026-05-11 13:01 · Yahoo
Top Midday Gainers
2026-04-09 18:05 · Yahoo
Forte Biosciences Announces Pricing of $150 Million Public Offering
2026-04-09 01:30 · Yahoo
Forte Biosciences Announces Proposed Public Offering
2026-04-08 20:02 · Yahoo
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
2026-03-31 20:01 · Yahoo
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
2026-03-17 20:01 · Yahoo
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
2026-02-25 17:00 · Yahoo
We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth
2026-02-18 11:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.